近日，私募股权公司德福资本对港交所上市公司赛生药业提出私有化邀约。本次私有化交易通过协议安排方式实施，实施所需的现金总额约为 87.9 亿港元（约为11.3 亿美元）。

高伟绅律师事务所为赛生药业提供法律服务；司力达律师事务所则为要约方财务顾问中金公司提供法律意见。

德福资本成立于 2010 年，是一家专注于中国医疗健康行业控股项目和成长期企业的投资公司。

赛生药业主要从事上市产品组合及其重点治疗领域（包括肿瘤及重症感染）在研产品开发与销售业务，其2021 年 3 月在港交所上市。

高伟绅团队由合伙人许文嘉和谭诗聪领导；

司力达团队的牵头合伙人为余嘉宝律师。

CC, Slaughter on SciClone’s $1.13 bln take-private deal in HK

Clifford Chance has advised SciClone Pharmaceuticals on its proposed take-private from HKEX by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).

The transaction was implemented via a scheme of arrangement, allowing for a cash consideration of up to approximately $1.13 billion.

Founded in 2010, GL Capital is an investment firm that focuses on buyouts and growth opportunities in China’s healthcare industry.

SciClone is engaged in developing and commercialising a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas, including oncology and severe infection. The company was listed in Hong Kong since March 2021.

The CC team was led by partners Christine Xu and Tommy Tam.

 The Slaughter team was headed by partner Bonita Yu.